Literature DB >> 15580363

Outcome research in palliative care: could it represent a new dimension of clinical research or clinical practice?

Davide Tassinari1, Marco Maltoni, Sergio Sartori, Manuela Fantini, Barbara Poggi, Alberto Ravaioli.   

Abstract

Outcome research is a new dimension of clinical research, and all fields of clinical medicine are involved in this kind of analysis. Overall survival and quality of life are the main outcomes identified in clinical oncology. The former must be the main outcome whenever possible; the latter has to be the main outcome when an improvement of overall survival cannot be expected. It follows that quality of life is the main outcome of palliative care, in which the patient instead of the disease represents the target of the clinical approach. In our critical paper, we review the meaning of clinical outcomes in palliative care, classifying the outcomes as main and surrogate outcomes, and the results of the trials as indexes of activity and efficacy of a treatment. We also review the main randomized clinical trials on the treatment of cancer cachexia, trying to define the role of the treatments in cachexia-related symptom control and quality of life improvement. Strictly related to outcome analysis is the dimension of pharmacoeconomic evaluation. The models of the different designs of pharmacoeconomic analysis are revisited in an attempt to conjugate the pharmacoeconomic evaluation with the particular dimension of palliative care.

Entities:  

Mesh:

Year:  2004        PMID: 15580363     DOI: 10.1007/s00520-004-0683-5

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  40 in total

1.  Thalidomide in patients with cachexia due to terminal cancer: preliminary report.

Authors:  E Bruera; C M Neumann; E Pituskin; K Calder; G Ball; J Hanson
Journal:  Ann Oncol       Date:  1999-07       Impact factor: 32.976

2.  Can we really consider quality of life as an outcome of palliative care?

Authors:  Davide Tassinari; Barbara Poggi; Manuela Fantini; Alberto Ravaioli; Sergio Sartori; Marco Maltoni
Journal:  J Pain Symptom Manage       Date:  2003-10       Impact factor: 3.612

3.  Eicosapentaenoic acid as a targeted therapy for cancer cachexia.

Authors:  Cristobal Belda-Iniesta; Javier de Castro Carpeno; Juan Angel Fresno Vara; Paloma Cejas Guerrero; Enrique Casado Saenz; Enrique Espinosa Arranz; Andres Redondo Sanchez; Jaime Feliu Battle; Manuel Gonzalez Baron
Journal:  J Clin Oncol       Date:  2003-12-15       Impact factor: 44.544

Review 4.  Principles of clinical trial design.

Authors:  Michelle Nottage; Lillian L Siu
Journal:  J Clin Oncol       Date:  2002-09-15       Impact factor: 44.544

5.  Megestrol acetate for anorexia in patients with far-advanced cancer: a double-blind controlled clinical trial.

Authors:  F De Conno; C Martini; E Zecca; A Balzarini; P Venturino; L Groff; A Caraceni
Journal:  Eur J Cancer       Date:  1998-10       Impact factor: 9.162

Review 6.  Quality of life in palliative care: principles and practice.

Authors:  Stein Kaasa; Jon Håvard Loge
Journal:  Palliat Med       Date:  2003-01       Impact factor: 4.762

7.  Effectiveness of palliative day care in improving pain, symptom control, and quality of life.

Authors:  Danielle M Goodwin; Irene J Higginson; Kathy Myers; Hannah-Rose Douglas; Charles E Normand
Journal:  J Pain Symptom Manage       Date:  2003-03       Impact factor: 3.612

8.  Megestrol acetate in cancer anorexia and weight loss.

Authors:  N S Tchekmedyian; M Hickman; J Siau; F A Greco; J Keller; H Browder; J Aisner
Journal:  Cancer       Date:  1992-03-01       Impact factor: 6.860

9.  Randomized comparison of four tools measuring overall quality of life in patients with advanced cancer.

Authors:  J A Sloan; C L Loprinzi; S A Kuross; A W Miser; J R O'Fallon; M R Mahoney; I M Heid; M E Bretscher; N L Vaught
Journal:  J Clin Oncol       Date:  1998-11       Impact factor: 44.544

10.  Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. American Society of Clinical Oncology.

Authors: 
Journal:  J Clin Oncol       Date:  1996-02       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.